Developing a novel therapy for Parkinson's Disease
Grant number: 509286 | Funding period: 2008 - 2010
By the time a patient first presents with symptoms of Parkinson's disease at the clinic, a large proportion (60-70%) of the cells in a specific part of the brain have been destroyed. This degeneration progresses until, within a few years, most of the cells have died. This project investigates the mechanisms involved in the continued death of cells and a possible new therapy that interrupts the progression. If the aims of this proposal are met, the drug could rapidly go to clinical trial.
Related publications (2)
L-3,4-dihydroxyphenylalanine (L-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease
Jessica L Billings, Sarah L Gordon, Tristan Rawling, Philip A Doble, Ashley I Bush, Paul A Adlard, David I Finkelstein, Dominic J Hare
High Order W02-Reactive Stable Oligomers of Amyloid-beta are Produced in vivo and in vitro via Dialysis and Filtration of Synthetic Amyloid-beta Monomer
Elysia Robb, Keyla Perez, Lin W Hung, Colin L Masters, Kevin J Barnham, Robert A Cherny, Ashley I Bush, Paul A Adlard, David I Finkelstein